Cost-effectiveness of Ambulatory Oxygen in improving quality of life in fibrotic lung disease: Preliminary evidence from the AmbOx Trial.
File(s)Ambox HE ERJrev_R2_6Sep19_TC.docx (63.95 KB)
Accepted version
Author(s)
Type
Journal Article
Abstract
Ambulatory oxygen may be cost-effective in improving quality of life in fibrotic lung disease. To be more conclusive, we need to understand societal willingness to pay for quality of life improvements and whether improvements are sustained. http://bit.ly/2pAiBJi
Date Issued
2020-02-01
Date Acceptance
2019-10-14
Citation
European Respiratory Journal, 2020, 55 (2)
ISSN
0903-1936
Publisher
European Respiratory Society
Journal / Book Title
European Respiratory Journal
Volume
55
Issue
2
Copyright Statement
© 2019 ERS. This is an author-submitted, peer-reviewed version of a manuscript that has been accepted for publication in the European Respiratory Journal, prior to copy-editing, formatting and typesetting. This version of the manuscript may not be duplicated or reproduced without prior permission from the copyright owner, the European Respiratory Society. The publisher is not responsible or liable for any errors or omissions in this version of the manuscript or in any version derived from it by any other parties. The final, copy-edited, published article, which is the version of record, is available without a subscription 18 months after the date of issue publication.
Sponsor
National Institute for Health Research
British Lung Foundation
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/31699838
PII: 13993003.01157-2019
Grant Number
CS-2013-13-017
C17-3
Subjects
Respiratory System
11 Medical and Health Sciences
Publication Status
Published
Coverage Spatial
England
Article Number
1901157
Date Publish Online
2020-02-06